Welcome to our dedicated page for Global Medical SEC filings (Ticker: GMRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Chiron Real Estate Inc., formerly Global Medical REIT Inc., files SEC reports documenting the public-company record of its net-lease medical REIT business and operating partnership structure. Its filings cover operating and financial results, earnings supplements, dividend and preferred-stock disclosures, shareholder voting matters, board composition and governance events.
Material-event filings also document capital-structure arrangements such as senior unsecured note facilities, master note and guaranty agreements, and related operating partnership obligations. The record includes the completed corporate name change from Global Medical REIT to Chiron Real Estate and associated issuer-status disclosures.
Chiron Real Estate Inc., formerly Global Medical REIT, reported 2025 results, updated its capital strategy and completed a corporate rebrand. For 2025, total revenue was $148.2 million and the company recorded a net loss of $6.9 million, driven in part by $13.0 million of property impairments.
FFO attributable to common stockholders and noncontrolling interest was $57.6 million ($3.97 per share and unit), while Core FFO reached $65.8 million ($4.53 per share and unit). Leverage was 44.4% at December 31, 2025, with $653.9 million of consolidated debt at a 3.74% weighted average interest rate and no maturities in 2026 or 2027.
The board kept the annualized common dividend at $3.00 per share but shifted to monthly payments, declaring $0.25 per share for each of April, May and June 2026. The company invested $7.1 million for a 49% interest in an active adult joint venture and set 2026 Core FFO guidance at $4.30 to $4.45 per share and unit. A key tenant, White Rock Medical Center, filed for Chapter 11, and Chiron carried a $1.4 million net receivable from its support efforts.
Global Medical REIT Inc. reported that director Henry Cole has informed the Board that he intends to step down as a director, effective at the Company’s 2026 Annual Meeting of Stockholders. He will not be nominated for re-election, and his service will end when his current term expires on the date of that meeting.
The Company states that Mr. Cole’s decision to step down is not due to any disagreement with Global Medical REIT Inc. on matters related to its operations, policies, or practices, indicating an orderly and planned board transition rather than a dispute-driven change.
Global Medical REIT Inc. disclosed an insider share purchase by its CEO and President. On 12/05/2025, the reporting person, who also serves as a director, bought 10,000 shares of common stock at a price of $32.51 per share. Following this transaction, the individual directly owned 54,774 shares of Global Medical REIT common stock and indirectly owned 3,404 additional shares through a spouse.
Global Medical REIT Inc. reported that director Ronald Marston has informed the Board that he intends to retire as a director, effective at the company’s 2026 Annual Meeting of Stockholders. He will not stand for re-election, and his service will conclude when his current term expires at that meeting. The company stated that Mr. Marston’s decision to retire is not due to any disagreement with Global Medical REIT regarding its operations, policies, or practices, indicating this is a planned governance transition rather than a response to a specific dispute.
Global Medical REIT Inc. is issuing a new series of preferred stock to raise capital through an underwritten public offering. The company agreed to sell 2,000,000 shares of its 8.00% Series B Cumulative Redeemable Preferred Stock at a public offering price of $25.00 per share, with a 30-day option for underwriters to purchase up to an additional 300,000 shares at the same price to cover over-allotments. The offering is expected to close on November 20, 2025, subject to customary conditions.
In connection with this, the operating partnership amended its agreement to allow issuance of up to 2,300,000 Series B Preferred Units with a $25.00 per unit liquidation preference, designed to mirror the economic terms of the preferred stock. The company intends to contribute the net proceeds from the Series B Preferred Stock to the operating partnership in exchange for an equal number of these units. Articles Supplementary designate 2,300,000 preferred shares as Series B, and if distributions on the Series B are not declared for any period, the company’s ability to pay distributions or make redemptions on junior or parity stock will be subject to specified restrictions.
Global Medical REIT Inc. (GMRE) reported an insider stock purchase by its Chief Financial Officer and Treasurer. On 11/14/2025, the executive bought 3,000 shares of common stock in an open-market transaction coded as a purchase at a price of $31.91 per share. Following this transaction, the officer beneficially owns 3,000 shares held directly. This filing reflects a personal investment decision by a senior financial executive rather than a corporate-level financing or strategic transaction.
Global Medical REIT Inc. (GMRE) reported insider share purchases by its CEO, President and Director on a Form 4. On 11/14/2025, the executive bought 4,093 shares of common stock at $32.41 per share and another 5,907 shares at $32.70 per share in open-market purchases. Following these transactions, the executive beneficially owns 44,774 shares directly and 3,404 shares indirectly through a spouse. The filing explains that the share amounts are presented on a post-split basis after a 1-for-5 reverse stock split completed on September 19, 2025, which also involved cash in lieu of a fractional share.
Global Medical REIT Inc. (GMRE) launched a primary offering of 2,000,000 shares of its 8.00% Series B Cumulative Redeemable Preferred Stock at $25.00 per share. The underwriting discount is $0.7875 per share, for gross proceeds of $50,000,000 and proceeds before expenses of $48,425,000. The company estimates net proceeds of approximately $48.1 million, or approximately $55.4 million if the 300,000‑share over‑allotment option is exercised in full.
Dividends accrue at 8.00% of the $25.00 liquidation preference ($2.00 per share annually), payable quarterly, with the first, a pro rata $0.388 per share, scheduled for January 31, 2026 to holders of record on January 15, 2026. The shares are perpetual, callable at the company’s option on or after November 20, 2030 at $25.00 plus accrued and unpaid dividends, and feature a Change of Control conversion right and special optional redemption.
GMRE intends to apply to list the Series B on the NYSE as “GMRE PrB.” Net proceeds will be contributed to the Operating Partnership for general corporate purposes, including funding acquisitions and repaying indebtedness under the Credit Facility.
Global Medical REIT (GMRE): Schedule 13G/A Amendment No. 1 filed by Prudential Financial, Inc. reports beneficial ownership of 297,464 shares, representing 2.2% of the common stock as of the reported date. Prudential holds shared voting and dispositive power over all 297,464 shares and no sole power.
The filing classifies Prudential as an HC and includes subsidiaries with reported holdings: PGIM, Inc. 267,248 shares (2.0%), Prudential Insurance Company of America 28,620 (0.2%), and PGIM Quantitative Solutions LLC 1,596 (0.0%). The certification states the securities were acquired and are held in the ordinary course, not to change or influence control.
Global Medical REIT Inc. (GMRE) launched a primary offering of Series B Cumulative Redeemable Preferred Stock. The shares carry a $25.00 per share liquidation preference, pay cumulative cash dividends quarterly in arrears on January 31, April 30, July 31 and October 31, commencing on January 31, 2026 to holders of record as of January 15, 2026. The stock is perpetual, with optional redemption on or after 2030 at $25.00 plus accrued and unpaid dividends.
Upon a Change of Control, holders may convert into GMRE common stock (subject to a share cap and alternative consideration mechanics), unless the shares are called for redemption. Voting rights are limited to protective provisions and the right to elect two directors if six or more quarterly dividends are in arrears. GMRE’s charter includes a 9.8% ownership limit per class or series to support REIT qualification.
GMRE intends to apply to list the new preferred on the NYSE as “GMRE PrB”, with trading expected within 30 days after initial delivery. Net proceeds will be contributed to the operating partnership for general corporate purposes, including acquisitions and repaying indebtedness under the Credit Facility.
Global Medical REIT Inc. (GMRE) launched a primary offering of Series B Cumulative Redeemable Preferred Stock. The shares carry a $25.00 per share liquidation preference, pay cumulative cash dividends quarterly in arrears on January 31, April 30, July 31 and October 31, commencing on January 31, 2026 to holders of record as of January 15, 2026. The stock is perpetual, with optional redemption on or after 2030 at $25.00 plus accrued and unpaid dividends.
Upon a Change of Control, holders may convert into GMRE common stock (subject to a share cap and alternative consideration mechanics), unless the shares are called for redemption. Voting rights are limited to protective provisions and the right to elect two directors if six or more quarterly dividends are in arrears. GMRE’s charter includes a 9.8% ownership limit per class or series to support REIT qualification.
GMRE intends to apply to list the new preferred on the NYSE as “GMRE PrB”, with trading expected within 30 days after initial delivery. Net proceeds will be contributed to the operating partnership for general corporate purposes, including acquisitions and repaying indebtedness under the Credit Facility.